Brief: Merck And Gilead Provide Update On Phase 3 Keynote-D46/Evoke-03 Study

Merck & Co

08/06/2026 21:47

June 8 (Reuters) - Gilead Sciences, Inc GILD.O:
MERCK AND GILEAD PROVIDE UPDATE ON PHASE 3 KEYNOTE-D46/EVOKE-03 STUDY
GILEAD: STUDY DID NOT ACHIEVE STATISTICAL SIGNIFICANCE FOR PROGRESSION-FREE OR OVERALL SURVIVAL
GILEAD:  DISCONTINUATION OF PHASE 3 KEYNOTE-D46/EVOKE-03 STUDY INVESTIGATING GILEAD'S TRODELVY IN COMBINATION WITH KEYTRUDA
GILEAD: NO CHANGES TO ONGOING TRODELVY OR MERCK STUDIES
GILEAD: SAFETY PROFILE OF TRODELVY IN COMBINATION WITH KEYTRUDA CONSISTENT WITH KNOWN SAFETY OF EACH AGENT
GILEAD:  NO NEW SAFETY SIGNALS WERE IDENTIFIED WITH TRODELVY IN COMBINATION WITH KEYTRUDA
Source text: ID:nBwbWZmRza
Further company coverage: GILD.O

 ((Reuters.Briefs@thomsonreuters.com;))